Results for tag: "GSK 3003891A"

GSK 3003891A is a vaccine developed by GlaxoSmithKline (GSK) for the prevention of respiratory syncytial virus (RSV) infection. RSV is a common virus that can cause severe respiratory illness in infants and young children. GSK 3003891A is a recombinant subunit vaccine, meaning it is made up of proteins from the virus that are not capable of causing infection. It is administered as a single dose to infants and young children, and is designed to provide long-term protection against RSV infection. The GSK 3003891A market is a rapidly growing segment of the global vaccine market. It is driven by the increasing prevalence of RSV infection, as well as the need for effective and safe vaccines to protect infants and young children from the virus. The market is highly competitive, with several major players, including GSK, Merck, Pfizer, and Sanofi, all competing for market share. Some of the major companies in the GSK 3003891A market include GSK, Merck, Pfizer, Sanofi, AstraZeneca, and Johnson & Johnson. These companies are all actively developing and marketing vaccines for the prevention of RSV infection. Show Less Read more